RecruitMe Clinical Trial

A Phase II Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimer's Disease
Study of BHV-4157 in Alzheimer's Disease (T2 Protect AD)
Sponsor:Biohaven Pharmaceuticals, Inc.
Enrolling:Male and Female Patients
Study Length:48 Weeks
Age Range:Between 50 and 85 years old
IRB Number:AAAR9079
U.S. Government ID:NCT03605667
Contact: Betina Idnay RN: 212-342-5615 / bsi2102@cumc.columbia.edu
Additional Study Information:

T2 Protect AD is a clinical trial testing the investigational drug troriluzole in people with mild to moderate Alzheimers disease (AD). The study is designed to determine whether this new drug can protect against, slow down, or potentially improve memory and thinking problems that increase as Alzheimers disease progresses.

Do You Qualify?
Are you between the ages of 50-85?YesNo
Do you have a diagnosis of Alzheimer's Disease (AD)YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Betina Idnay RN
Email: bsi2102@cumc.columbia.edu
Phone: 212-342-5615